Tourmaline Bio Inc [TRML] stock is trading at $18.80, up 10.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TRML shares have gain 30.74% over the last week, with a monthly amount glided 42.10%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tourmaline Bio Inc [NASDAQ: TRML] stock has seen the most recent analyst activity on March 06, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $42. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $50. On November 11, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $49 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $41 on December 15, 2023. Truist started tracking with a Buy rating for this stock on November 17, 2023, and assigned it a price target of $43. In a note dated October 31, 2023, Guggenheim initiated an Buy rating and provided a target price of $50 on this stock.
Tourmaline Bio Inc [TRML] stock has fluctuated between $11.87 and $46.36 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Tourmaline Bio Inc [NASDAQ: TRML] shares were valued at $18.80 at the most recent close of the market. An investor can expect a potential return of 144.68% based on the average TRML price forecast.
Analyzing the TRML fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.22 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.95 points at the first support level, and at 17.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.24, and for the 2nd resistance point, it is at 19.67.
Ratios To Look Out For
For context, Tourmaline Bio Inc’s Current Ratio is 40.33. As well, the Quick Ratio is 40.33, while the Cash Ratio is 3.42.
Transactions by insiders
Recent insider trading involved Kulkarni Sandeep Chidambar, CEO, that happened on Aug 21 ’24 when 1779.0 shares were purchased. CEO, Kulkarni Sandeep Chidambar completed a deal on Aug 16 ’24 to buy 5221.0 shares.
